RCKT Stock Up as FDA Accepts Resubmitted BLA for Gene Therapy
Yahoo Finance · Oct 15, 2025 · Chemomab Therapeutics Ltd DRC (CMMB)
Rocket Pharmaceuticals surges as the FDA accepts its resubmitted BLA for Kresladi, a gene therapy targeting the rare LAD-I disorder.
Not investment advice. Cached headline, not a full reprint.